A Prospective Study of Body Fat Redistribution, Lipid, and Glucose Parameters in HIV-Infected Patients Initiating Combination Antiretroviral Therapy

REFERENCES

• Palella FJ, Delaney KM, Moorman AC, et al. Declining mor-bidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338:853–860.
   PubMed Web of Science ®Google Scholar
• Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349:1294.
   PubMed Web of Science ®Google Scholar
• Wanke C. Epidemiological and clinical aspects of the met-abolic complications of HIV infection. The fat redistribution syndrome. AIDS. 1999;13:1287–1293.
   PubMed Web of Science ®Google Scholar
• Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with HIV type I protease inhibitors. Clin Infect Dis. 1998;27:65–67.
   PubMed Web of Science ®Google Scholar
• Carr A, Samaras K, Burton S et al. A syndrome of pe-ripheral lipodystrophy, hyperlipidaemia and insulin resis-tance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F56.
   Web of Science ®Google Scholar
• Carr A, Samara K, Thorisdottir A, et al. Diagnosis, predic-tion, and natural course of HIV-1 protease-inhibitor associ-ated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet. 1999;353;2093–2099.
   PubMed Web of Science ®Google Scholar
• Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting inpatients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659–1667.
   PubMed Web of Science ®Google Scholar
• Bogner JR, Vielhauer V, Beckmann RA, Michl G, et al. Stavudine versus zidovudine and the development of li-podystrophy. J Acquir Immune Defic Syndr 2000;27:237–244.
   Web of Science ®Google Scholar
• Shlay JC, Vinsegarwala F, Bartsch G, Wand J, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to Didanosine and Stavudine vs. Aba-cavir and Lamivudine. J Acquir Immune Defic Syndr 2005; 38:147–155.
   PubMed Web of Science ®Google Scholar
• Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoat-rophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14(3):F25–32.
   PubMed Web of Science ®Google Scholar
• Brinkman K, Smeitink H, Rominjn J, Reiss P. Mitochon-drial toxicity induced by nucleoside-analogue reverse tran-scriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy related lipodystrophy. Lancet. 1999; 354:1112–1115.
   PubMed Web of Science ®Google Scholar
• Saghayam S, Kumarasamy N, Cecelia AJ, et al. Weight and body shape changes in a treatment-naïve popula-tion after 6 months of Nevirapine-based generic highly active antiretroviral therapy in South India. Clin Infect Dis. 2007;44:295–300.
   PubMed Web of Science ®Google Scholar
• Haubrich R, Riddler S, DiRienzo G, Komarow L, et al. Meta-bolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, Pl-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. Presented at the 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles, CA.
   Google Scholar
• Safrin S, Grunfeld. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493–2505.
   PubMed Web of Science ®Google Scholar
• Brown TT, Chu H, Wang Z, Palella FJ, Kingsley L, et al. Lon-gitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS. 2007;21:1731–1738.
   PubMed Web of Science ®Google Scholar
• Visnegarwala F, Shlay JC, Vaughn B, Gibert CL, et al. Effects of HIV infection on body composition changes among men of different racial/ethnic origins. HIV Clin Trials. 2007;8(3):145–154.
   PubMed Web of Science ®Google Scholar
• Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465–471.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia and lipodystroply. A 5-year cohort study. Arch Intern Med. 2000;160(13):2050–2056.
   PubMed Web of Science ®Google Scholar
• Tien PC, Barron Y, Justman JE, Hyman C, et al. Antiretro-viral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS. 2007;21(5):297–305.
   PubMed Web of Science ®Google Scholar
• Currier J, Scherzer R, Bacchetti P, Heymsfield S, et al. Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 2008; 48(1):35–43.
   PubMed Web of Science ®Google Scholar
• Gharakhanian S. The HIV associated lipodystrophy syn-drome: Research, results yet more questions. AIDS. 2001; 15:271–273
   PubMed Web of Science ®Google Scholar
• Lee E, Walmsley SL, Fantus G. New onset diabetes mel-litus associated with protease inhibitor therapy in an HIV-infected patient: Case report and review. Can Med Assoc J. 1999;161:161–164.
   Web of Science ®Google Scholar
• Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 200115: 231–239.
   Google Scholar
• Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenback M, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretro-viral drugs associated with different lipid profiles? J Infect Dis. 2004;189: 1056–1074.
   PubMed Web of Science ®Google Scholar
• Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome. AIDS Reader 2000;10:546–550.
   PubMedGoogle Scholar
• Duran S, Savész M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS. 200115: 2441–2444.
   Google Scholar
• Blanch J, Rousaud A, Martinez E, De Lazzari E, et al. Fac-tors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis. 2004;38:1464–1470.
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Carr A, et al. Reversibility of lipoatro-phy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS. 2004;18:1029–1036.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Baldwin C, Langroudi B, et al. A 48-week, ran-domized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipid-emia and peripheral lipoatrophy. J Acquir Immune Defic Syndr 2003;33:22–28.
   PubMed Web of Science ®Google Scholar
• Falutz J, Alias S, Blot K, Potvin D, Kotler D, et al. Metabolic effects of growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370.
   PubMed Web of Science ®Google Scholar
• Carr A, Workman C, Carey D, Rogers G, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet. 2004;363(9407):429–438.
   PubMed Web of Science ®Google Scholar
• Cavalcanti R, Raboud J, Shen S, Kain, KC, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosi-glitazone for HIV-related lipodystrophy. J Infect Dis. 2007; 195(12):1754–1761.
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005; 352:48–62.
   PubMed Web of Science ®Google Scholar
• DAD Study Group, Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–1735.
   PubMed Web of Science ®Google Scholar
• Bozzette S, Ake C, Tam H, Phippard A, et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008;47(3):338–341.
   PubMed Web of Science ®Google Scholar
• Molarius A, Seidell JC. Selection of anthropometric indi-cators for classification of abdominal fatness-a critical review. Int J Obesity. 1998;22:719–727.
   PubMed Web of Science ®Google Scholar
• Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2192.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabe-tes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653.
   PubMed Web of Science ®Google Scholar
• Mallal SA, John M, Moore CB, et al. Contribution of nucleo-side analogue reverse transcriptase inhibitors to subcu-taneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309–1316.
   PubMed Web of Science ®Google Scholar
• Lowe SH, Hassink EA, van Eck-Smitt BL, Borleffs JC, et al. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: A substudy from the Antiretro-viral Regimen Evaluation Study (ARES). HIV Clin Trials. 2007;8(5):337–344.
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V, et al. Increased risk of li-poatrophy under stavudine in HIV-1 infected patients: Re-sults of a substudy from a comparative trial. AIDS. 2002; 16:2441–2454.
   Web of Science ®Google Scholar
• Chene G, Angelini E, Cotte L, Lang J, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002;34:649–657.
   PubMed Web of Science ®Google Scholar
• Mallon P, Miller J, Cooper DA, Carr A. Prospective evalu-ation of the effects of antiretroviral therapy on body com-position in HIV-infected men starting therapy. AIDS. 2003; 17:971–979.
   PubMed Web of Science ®Google Scholar
• Shlay JC, Bartsch G, Peng G, Wang J, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-non-nucleoside reverse transcriptase inhibitor, or protease inhibitor plus nonnucleoside reverse transcriptase inhibi-tor-based strategy. J Acquir Immune Defic Syndr. 2007; 44:506–517.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Parker RA, Komarow L, Grinspoon SK, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006;41:590–597.
   PubMed Web of Science ®Google Scholar
• Dube MP, Komarow L, Mulligan K, Grinspoon SK, et al. Long-term body fat outcomes in antiretroviral-naïve par-ticipants randomized to Nelfinavir or Efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a Substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007;45(5):508–514.
   PubMed Web of Science ®Google Scholar
• Dube MP, Qian D, Edmonson-Melancon H, Sattler FR, et al. Prospective, intensive study of metabolic changes as-sociated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002;35:475–481
   PubMed Web of Science ®Google Scholar
• Jensen MD, Kanaley JA, Reed JF, Sheedy PF. Measure-ment of abdominal and visceral fat with computed tomog-raphy and dual-energy x-ray absorptiometry. Am J Clin Nutr 1995;61:274–278.
   PubMed Web of Science ®Google Scholar
• Bonnet E, Delpierre C, Sommet A, Marion-Latard F, et al. Total body composition by DM of 241 HIV-negative men and 162 HIV-infected men: Proposal of reference values for defining lipodystrophy. J Clin Dens/tom. 2005;8(3):287–292.
   PubMed Web of Science ®Google Scholar
• Salamone LM, Fuerst T, Visser M, et al. Measurement of fat mass using DEM: A validation study in elderly adults. J Appl PhysioL 2000;89:345–352.
   PubMed Web of Science ®Google Scholar
• Cavalcanti RB, Cheung AM, Raboud J, Walmsley S. Repro-ducibility of DM estimations of body fat in HIV lipodystro-phy. J Clin Dens. 2005;8(3):293–297.
   PubMed Web of Science ®Google Scholar
• Palella FJ, Cole SR, Chmiel JS, Riddler SA, et al. Anthro-pometrics and examiner-reported body habitus abnormali-ties in the multi-center AIDS cohort study. Clin Infect Dis. 2004;38:903–907.
   PubMed Web of Science ®Google Scholar
• Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of li-podystrophy in HIV-1-infected patients treated with prote-ase inhibitors: A prospective cohort study. Lancet. 2001; 357:592–598.
   PubMed Web of Science ®Google Scholar
• Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in anti-retroviral-näive patients: A randomized trial. JAMA. 2004; 292(2):266–268.
   PubMed Web of Science ®Google Scholar
• Pozinak AL, Gallany JE, DeJesus E, Arribas JR, Gazzard B, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirens in antiretroviral-naïve patients. Virologic, immu-nologic, and morphologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006;43:535–540.
   PubMed Web of Science ®Google Scholar